Á lódáil...
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a median survival of 3 years despite chemoimmunotherapy. Rituximab, a chimeric anti–CD20 monoclonal antibody (mAb), has shown only modest activity as single agent in MCL. The humanized mAb milatuzumab targets CD74, an integral membra...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
American Society of Hematology
2011
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3099572/ https://ncbi.nlm.nih.gov/pubmed/21228331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-303354 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|